D. E. Shaw & Co. Inc. Trims Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

D. E. Shaw & Co. Inc. lowered its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 15.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,723,706 shares of the biotechnology company's stock after selling 660,971 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 2.45% of Heron Therapeutics worth $5,697,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of HRTX. Congress Park Capital LLC boosted its holdings in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after acquiring an additional 477,417 shares during the period. Quinn Opportunity Partners LLC bought a new stake in shares of Heron Therapeutics during the 4th quarter valued at about $581,000. JPMorgan Chase & Co. grew its position in Heron Therapeutics by 172.2% in the fourth quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock worth $861,000 after acquiring an additional 356,053 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Heron Therapeutics during the fourth quarter worth approximately $459,000. Finally, CM Management LLC increased its holdings in shares of Heron Therapeutics by 40.0% in the fourth quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock worth $1,071,000 after buying an additional 200,000 shares during the period. Institutional investors own 80.01% of the company's stock.

Analyst Ratings Changes

HRTX has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, March 8th.

Heron Therapeutics Stock Performance

NASDAQ HRTX remained flat at $1.92 during mid-day trading on Tuesday. 881,588 shares of the company were exchanged, compared to its average volume of 2,309,019. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93. The business's 50-day moving average price is $2.13 and its two-hundred day moving average price is $1.82. The firm has a market cap of $292.92 million, a PE ratio of -10.67 and a beta of 1.33.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million. On average, research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.